NL-OMON30348已完成4 期
A twelve-month, multicenter, open-label, randomized study of the safety, tolerability and efficacy of Certican* with Simulect, corticosteroids and two different exposure levels of tacrolimus in de novo renal transplant recipients - NA
PPD0 个研究点目标入组 36 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Male or female 18-65 years old
- •Primary transplant from cadaveric, living-unrelated or non-HLA identical living related donor
- •Cold Ischemia time <30 h
- •Negative pregnancy test in female
- •Willing and capable to give written informed consent
排除标准
- •Multiple organtransplants
- •Non-heart beating donor
- •Hypercholestrolemia >9,1 mmol/L
- •Leucocytes <3
- •HIV, HBSag or anti HBC AB positive
- •Allergy to one of the drugs
- •Malignancy apart from localised skin tumors
- •Unable to cooperate or communicate with the investigator
研究者
相似试验
进行中（未招募）
1 期
A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination compared to standard CNI, mycophenolate mofetil and steroid regimen in paediatric renal transplant recipients with a 24-month additional safety follow-up.Prevention of acute rejection in paediatric recipients of a renal transplantMedDRA version: 14.1Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-024381-21-ITOVARTIS FARMA106
进行中（未招募）
不适用
A 12-month, multicenter, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican (1.5 mg/day starting dose) with reduced Neoral dose versus MMF with standard Neoral dose in de novo heart transplant recipientsProphylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic cardiac transplant. The drug should be used in combination with ciclosporin for microemulsion and corticosteroids.MedDRA version: 6.1Level: PTClassification code 10019315EUCTR2004-001052-36-ITOVARTIS FARMA
已完成
3 期
A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of Certican-based regimen versus calcineurin inhibitor-based regimen in de novo liver transplant recipientTherapy after Liver transplant10019654NL-OMON30363ovartis40
进行中（未招募）
不适用
A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose versus MMF with standard Neoral® dose in de novo heart transplant recipients. - RAD2411EUCTR2004-001052-36-DEovartis Pharma Services AG176
进行中（未招募）
不适用
A 12-month, multi-center, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican® (1.5 mg/day starting dose) with reduced Neoral® dose versus MMF with standard Neoral® dose in de novo heart transplant recipients. - RAD2411EUCTR2004-001052-36-ESovartis Farmacéutica S.A176